FDA decisions on BPC-157 center on its status under Section 503A bulk drug substance rules for compounding pharmacies. Previously placed in Category 2 due to immunogenicity risks and limited clinical data, the substance was removed from that list in April 2026. The Pharmacy Compounding Advisory Committee then reviewed it at its July 23-24, 2026 meeting and voted 8-6 with one abstention to recommend inclusion on the 503A bulks list for ulcerative colitis use. FDA has not yet issued a final determination on Category 1 eligibility, which would permit lawful compounding under prescriptions. Traders monitor agency follow-through, any additional nominations or dockets, and broader peptide reclassification signals from HHS.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoNOWE
Aug 31, 2026
August 31, 2026
13%
December 31, 2026
54%
$2,598 Wol.
August 31, 2026
$892 Wol.
13%
December 31, 2026
$1,706 Wol.
54%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.FDA decisions on BPC-157 center on its status under Section 503A bulk drug substance rules for compounding pharmacies. Previously placed in Category 2 due to immunogenicity risks and limited clinical data, the substance was removed from that list in April 2026. The Pharmacy Compounding Advisory Committee then reviewed it at its July 23-24, 2026 meeting and voted 8-6 with one abstention to recommend inclusion on the 503A bulks list for ulcerative colitis use. FDA has not yet issued a final determination on Category 1 eligibility, which would permit lawful compounding under prescriptions. Traders monitor agency follow-through, any additional nominations or dockets, and broader peptide reclassification signals from HHS.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Rynek otwarty: Jun 22, 2026, 10:10 PM ET
Wolumen
$2,598Data zakończenia
Dec 31, 2026Rynek otwarty
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.FDA decisions on BPC-157 center on its status under Section 503A bulk drug substance rules for compounding pharmacies. Previously placed in Category 2 due to immunogenicity risks and limited clinical data, the substance was removed from that list in April 2026. The Pharmacy Compounding Advisory Committee then reviewed it at its July 23-24, 2026 meeting and voted 8-6 with one abstention to recommend inclusion on the 503A bulks list for ulcerative colitis use. FDA has not yet issued a final determination on Category 1 eligibility, which would permit lawful compounding under prescriptions. Traders monitor agency follow-through, any additional nominations or dockets, and broader peptide reclassification signals from HHS.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Wolumen
$2,598Data zakończenia
Dec 31, 2026Rynek otwarty
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...FDA decisions on BPC-157 center on its status under Section 503A bulk drug substance rules for compounding pharmacies. Previously placed in Category 2 due to immunogenicity risks and limited clinical data, the substance was removed from that list in April 2026. The Pharmacy Compounding Advisory Committee then reviewed it at its July 23-24, 2026 meeting and voted 8-6 with one abstention to recommend inclusion on the 503A bulks list for ulcerative colitis use. FDA has not yet issued a final determination on Category 1 eligibility, which would permit lawful compounding under prescriptions. Traders monitor agency follow-through, any additional nominations or dockets, and broader peptide reclassification signals from HHS.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania